AbbVie
ABBV
2,969 hedge funds and large institutions have $166B invested in AbbVie in 2022 Q3 according to their latest regulatory filings, with 137 funds opening new positions, 1,304 increasing their positions, 1,156 reducing their positions, and 130 closing their positions.
13% more call options, than puts
Call options by funds: $2.32B | Put options by funds: $2.05B
13% more repeat investments, than reductions
Existing positions increased: 1,304 | Existing positions reduced: 1,156
1.08% more ownership
Funds ownership: 68.95% → 70.04% (+1.1%)
5% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 130
1% less funds holding
Funds holding: 3,005 → 2,969 (-36)
11% less capital invested
Capital invested by funds: $186B → $166B (-$20.1B)
16% less funds holding in top 10
Funds holding in top 10: 330 → 278 (-52)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$2.31B |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$1.42B |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$538M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$383M |
| 5 |
CIAS
CFS Investment Advisory Services
Totowa,
New Jersey
|
+$355M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$902M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$432M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$343M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$325M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$281M |
ABBV Hedge Fund Activity: Q3 2022 in Review
2,969 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2022, worth a combined $166B — down 11% from $186B a quarter earlier.
Buyers outnumbered sellers: 137 funds opened new ABBV positions and 130 closed out — a net gain of 7 holders — while 1,304 added to existing stakes and 1,156 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $2.31B. The largest seller was T. Rowe Price Associates, cutting an estimated $902M.
- 2,969 institutional investors held AbbVie (ABBV) as of Q3 2022, down from 3,005 in Q2 2022.
- Funds reported $166B of AbbVie stock for Q3 2022, down 11% quarter-over-quarter.
- 137 funds opened new AbbVie positions in Q3 2022 and 130 closed out, a net change of +7 holders.
- The largest AbbVie buyer in Q3 2022 was Janus Henderson Group, an estimated $2.31B added.
- The largest AbbVie seller in Q3 2022 was T. Rowe Price Associates, an estimated $902M sold.
Based on aggregated 13F filings for Q3 2022.